New thematic issue highlights link between hyperuricemia, gout and kidney disease

The increasing prevalence of both gout and chronic kidney disease has led to a growing interest in the association between hyperuricemia (an abnormally high level of uric acid in the blood) and kidney disease.

A new thematic issue of The Open Urology & Nephrology Journal, titled 'Current Perspectives in Hyperuricemia, Gout and the Kidney,' reports on the interplay of various factors, particularly the role of the kidney in uric acid excretion on the one hand, and the possible impact of hyperuricemia on progression of renal disease on the other. The common patho-physiological link appears to be the chronic, low-grade, systemic inflammation that is intrinsic to both conditions, and that may explain some of the perplexing observations noted in these clinical conditions.

This thematic issue discusses the effect of the activation of the innate immune system, through stimulation of the NLRP3 inflammasome, leading to the subsequent generation of interleukins and the release of cytokines and chemokines, and how these factors interact in the complex interplay between hyperuricemia, gout and kidney disease.

Additionally, with the recent updates in clinical management guidelines for acute and chronic gout, and given that there are special considerations in specific patient populations, articles in the issue incorporate recommendations from three different medical perspectives: the primary care physician, the rheumatologist and the nephrologist.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients